Parameter
| Biomarker | BRAF V600E (mutation) | Full name | B-Raf proto-oncogene, serine/threonine kinase V600E mutation | Molecular Type | Nucleic acids (DNA mutations) |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Diagnosis and targeted treatment options | ||
| Disease | Cholangiocarcinoma (CCA) | Disease Subtypes | / | ||
| Organ | Bile duct/Liver | Test Sample / Technology Platform | Organization/plasma (NGS, ddPCR) | ||
| Pathobiological Mechanisms | Mutations activate the MAPK pathway and promote tumor proliferation and invasion | ||||
| Clinical Availability Status | Clinical validation; About 3% of patients with iCCA carry it | ||||
| Notes and Dynamics | dabrafenib+trametinib (ORR 47%) for patients without other treatment options; Tumor-agnostic therapy was indicated | ||||